Ewch i’r prif gynnwys

Dirywiad retinol a heneiddio

Mae'r cynnwys hwn ar gael yn Saesneg yn unig.

Age related eye disease accounts for more than 70% of all vision loss in the UK. 

We are seeking to reduce the prevalence of vision loss by developing new treatment and biomarker technologies. This is key to understanding healthy and unhealthy retinal ageing.

Our work extends from basic physiology to clinical trials. The tests we are developing are exquisitely sensitive to the subtle changes in the retina associated with conditions such as:

  • age-related macular degeneration (AMD)
  • diabetic eye disease
  • glaucoma.

Current research areas are:

  • outer retinal functional imaging
  • clinical trials for early stage AMD
  • establishment of normative databases
  • the development of novel visual field tests
  • optical coherence tomography.

We use a wide range of established and novel imaging, psychophysical and electrophysiological techniques to probe all aspects of retinal form and function.

Collaborations with engineers, statisticians, economists, clinicians, and researchers from around the world, together with good links with patient groups, aims to ensure that the group is at the vanguard of developments.

Theme lead

Yr Athro Tom Margrain

Yr Athro Tom Margrain

Reader, Director of Innovation and Engagement

+44 29208 76118